

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – November 9, 2020



WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

(State or other jurisdiction  
of incorporation)

1-8036

(Commission File Number)

23-1210010

(IRS Employer  
Identification No.)

530 Herman O. West Drive, Exton, PA

(Address of principal executive offices)

19341-0645

(Zip Code)

Registrant's telephone number, including area code: **610-594-2900**

Not Applicable

(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$0.25 per share	WST	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 4, 2020, George L. Miller informed the Company that he intends to retire effective at the end of February 2021. He will step down in his role as Senior Vice President, General Counsel and Corporate Secretary effective December 8, 2020 after which he will become a Special Advisor to our President and Chief Executive Officer, Eric M. Green where, among other things, he will assist with transition of his duties. His departure is not based on any disagreement with the Company relating to its operations, policies or practices. In connection with his retirement, no additional compensation was agreed.

Kimberly Banks MacKay, 55, has agreed to join the Company as its new Senior Vice President, General Counsel and Corporate Secretary. She will join the Company on December 2, 2020 and will report directly to Mr. Green. A copy of the press release issued by the Company announcing the appointment of Ms. MacKay is filed as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(d)	<u>Exhibit No.</u>	<u>Description</u>
	99.1	West Pharmaceutical Services, Inc. Press Release, dated November 9, 2020.
	104	The cover page from the Company's Current Report on Form 8-K, dated November 9, 2020, formatted in Inline XBRL.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ Bernard J. Birkett

Bernard J. Birkett

Senior Vice President and Chief Financial Officer

November 9, 2020

## EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">West Pharmaceutical Services, Inc. Press Release, dated November 9, 2020.</a>
104	The cover page from the Company's Current Report on Form 8-K, dated November 9, 2020, formatted in Inline XBRL.



**Exhibit 99.1**

**Investor Contact:**

Quintin Lai  
Vice President, Investor Relations  
+1-610-594-3318  
[Quintin.Lai@westpharma.com](mailto:Quintin.Lai@westpharma.com)

**Media Contact:**

Michele Pelkowski  
Vice President, Global Communications  
+1-610-594-3054  
[Michele.Pelkowski@westpharma.com](mailto:Michele.Pelkowski@westpharma.com)

**West Appoints Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary**

Exton, Pa., November 9, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced it has appointed Kimberly Banks MacKay to serve as Senior Vice President General Counsel and Corporate Secretary, effective December 8, 2020. Ms. MacKay will succeed George L. Miller, who announced his intention to retire in February 2021. Mr. Miller will remain at West through the end of February as a Special Advisor to oversee the transition of duties.

Ms. MacKay joins West from The Segal Group, a privately held firm specializing in employee benefits and investment consulting where she served as Senior Vice President General Counsel and Corporate Secretary. Prior to Segal, she served for over 15 years in roles of increasing responsibility at Novartis, including Head U.S. Legal for Novartis Business Services, Deputy Compliance Officer for Novartis Pharmaceuticals Corporation and Lead Counsel for a large Novartis business unit. Before joining Novartis, Kim practiced securities law at MetLife, Lucent Technologies and Milbank in New York. She also held a Federal clerkship and spent several years in commercial banking.

“After an extensive search, we are pleased that Kimberly is joining our West team,” said Eric M. Green, President and Chief Executive Officer, West. “She brings significant legal experience from her previous roles along with a deep understanding of the regulated environment in which we operate. As we continue to advance the importance of our mission as the leader in integrated containment and delivery of injectable medicines, Kimberly’s knowledge of this industry, as well as her innovative and collaborative leadership style will be an asset to our team.”

“I am excited to join such a strong company and Senior leadership team. West has an impressive track record of providing innovative and impactful solutions for their customers and ultimately the patients. I look forward to contributing to the next phase of the company’s success,” said Ms. MacKay.

Kimberly earned her Juris Doctor from Rutgers University School of Law and her bachelor’s degree in Economics from Princeton University.

## **About West**

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2019 sales of \$1.84 billion reflect the daily use of more than 100 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

*All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.*